0001169245-22-000013.txt : 20220228
0001169245-22-000013.hdr.sgml : 20220228
20220228192512
ACCESSION NUMBER: 0001169245-22-000013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220224
FILED AS OF DATE: 20220228
DATE AS OF CHANGE: 20220228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Birchall Jonathan
CENTRAL INDEX KEY: 0001892776
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38697
FILM NUMBER: 22692950
MAIL ADDRESS:
STREET 1: C/O PHASEBIO PHARMACEUTICALS, INC.
STREET 2: 1 GREAT VALLEY PARKWAY, SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001169245
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030375697
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: (610) 981-6500
MAIL ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: Phase Biosciences Inc
DATE OF NAME CHANGE: 20061013
FORMER COMPANY:
FORMER CONFORMED NAME: DT BIOSCIENCES INC
DATE OF NAME CHANGE: 20020315
4
1
wf-form4_164609429220987.xml
FORM 4
X0306
4
2022-02-24
0
0001169245
PhaseBio Pharmaceuticals Inc
PHAS
0001892776
Birchall Jonathan
C/O PHASEBIO PHARMACEUTICALS, INC.
1 GREAT VALLEY PARKWAY, SUITE 30
MALVERN
PA
19355
0
1
0
0
Chief Commercial Officer
Restricted Stock Unit
2022-02-24
4
A
0
11250
0
A
Common Stock
11250.0
11250
D
Employee Stock Option (right to buy)
1.13
2022-02-24
4
A
0
52500
0
A
2022-02-24
Common Stock
52500.0
52500
D
Each Restricted Stock Unit is the economic equivalent of one share of PhaseBio Pharmaceuticals, Inc. common stock and is converted into common stock upon vesting subject to the reporting person's continued service through each such date.
These Restricted Stock Units vest in equal one-third amounts on April 1, 2023, 2024, and 2025.
The shares subject to the option shall vest in equal monthly installments over 48 months from February 24, 2022, subject to the reporting person's continued service through each such date.
/s/ John P. Sharp, Attorney-in-fact
2022-02-28